Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Rebates Would Contribute More Than Half Of Medicare Savings In White House Plan

This article was originally published in The Pink Sheet Daily

Executive Summary

Plan seeks to cut Medicare costs by a total of $248 billion over 10 years, with mandatory rebates in Part D contributing $135 billion.

You may also be interested in...



CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

Beyond ObamaCare: Big Pharma, Health Reform and the 2012 Elections

Most everyone can agree that health care costs are spiraling out of control. President Obama and his Republican challenger Mitt Romney each say they have a plan to cut spending. But while those are being debated, a high-profile group of former Obama advisers are suggesting something much more radical: a systematic change in the way we pay for health care. Could it be a blueprint for a second Obama term?

CMS Budget Plan: $1 Bil. Increase For Administrative Activities Is New, But Drug Policy Proposals Are Old

CMS budget plan reprises Medicare drug rebates for dual eligibles, eliminating brand/generic patent settlements and other unsuccessful Rx proposals.

Related Content

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel